Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia (LLC-LENAR-08)

MD Anderson International Spain SA

Status and phase: Completed; Phase 1

Conditions: Chronic Lymphocytic Leukemia

Treatments: Drug: Lenalidomida and Rituximab

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT01185262

LLC-LENAR-08 (Other Identifier)

Details and patient eligibility

About

The rationale for combining lenalidomide with rituximab derives from preclinical observations suggesting that lenalidomide may enhance the ADCC (antigen-dependent cellular cytotoxicity) triggered by monoclonal antibodies such as rituximab. Lenalidomide augments NK cytotoxicity by increasing CD56dimCD3 subset, in addition to inducing IL-2 in T cells. These results provide the cellular and molecular basis for the use of lenalidomide as an adjuvant in immunotherapeutic strategies of monoclonal antibodies (mAb)-based therapies. The combination lenalidomide-rituximab was tested in lymphoma cell lines but not specifically on CLL cell lines. However the observed synergism was attributed to NK cells expansion, thus lending support to the notion that this synergism may operate in other B-cell lymphoproliferative malignancies.

The objective was to develop a non-cytotoxic and effective treatment for CLL that would fulfill an unmet medical need, as a significant proportion of CLL patients are elderly and frail. These patients experience an excess in chemotherapy induced toxicity, often preventing the completion of the planned treatment.

Enrollment: 25 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Recurrent and refractory CLL patients that have received at least one previous treatment with purine analogs.
• Adequate liver function and renal function.
• ECOG performance status ≤ 2.
• Signed informed consent
• Male and female patients who are fertile agree to use an effective barrier method of birth control to avoid pregnancy.

Exclusion criteria

• Positive serological markers for hepatitis B with the exception of HBsAc in previously vaccinated patients
• Pregnant patients
• HIV infection
• Concurrent chemotherapy or immunotherapy
• Other malignancy within the last 2 years, except for localized cutaneous carcinoma
• Neurological impairment precluding understanding of protocol and the entailed visits and procedures.
• Patients with Renal insufficiency that requires dialysis.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

25 participants in 1 patient group

Lenalidomida, Rituximab

Experimental group

Description:

Phase I: Lenalidomide will be administered from day 1 to 21 of 28 days cycles, escalating doses (from 2,5mg to 25 mg).Rituximab dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).

Treatment:

Drug: Lenalidomida and Rituximab